OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OPKO Health (OPK) closed the most recent trading day at $4.02, making no change from the previous trading session.

OPKO Health (OPK) Flat As Market Gains: What You Should Know

Opko is generating strong revenue from testing for the coronavirus, while its HGH drug looks quite promising. As a result, OPK stock is a buy.

Opko Stock Is a Covid-19 Testing Name Worth Betting On

OPKO Health (OPK) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why OPKO Health (OPK) Stock Might be a Great Pick

OPKO Health (OPK) continues to benefit from lucrative prospects in RAYALDEE and BioReference platforms.

Here's Why You Should Invest in OPKO Health (OPK) Stock Now

Opko is conducting a coronavirus treatment study, as well as providing Covid-19 tests. That gives OPK stock two ways to play the virus.

Buy Opko Stock For Two Ways to Play the Ongoing Pandemic

ELMWOOD PARK, N.J., July 1, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR and antibody tests for nursing home and live-in facility employees. On May 10, New York State mandated that all...

OPKO Health's BioReference Laboratories Reports Results of COVID-19 Testing for Almost One Quarter of a Million Nursing Home and Live-in Facility Employees

As of late, it has definitely been a great time to be an investor in OPKO Health.

OPKO Health's Shares March Higher, Can It Continue?

OPKO Health, Inc. (OPK) CEO Phillip Frost Hosts 2020 Annual Meeting of Stockholders (Transcript)

Alpha Pro Tech

CVS Health

Labcorp Holdings Inc

Moderna

Regeneron Pharmaceuticals

I have previously discussed my views of the coronavirus pandemic, which included the fact that many states opened too early and that greater testing was needed.

The New Normal Of The Coronavirus Pandemic: Investment Implications

Emergent BioSolutions

Which stock wins in a battle between a COVID-19 testing leader and the top contract manufacturer for COVID-19 vaccines?

Better Coronavirus Stock: OPKO Health or Emergent Biosolutions?

MIAMI, June  09, 2020  (GLOBE NEWSWIRE) -- Following last October’s  announcement  of successful results of the global Phase 3 study of once-weekly somatrogon, an investigational agent for the treatment of pediatric growth hormone deficiency (pGHD), OPKO Health Inc. (NASDAQ: OPK) announced today that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN® (somatropin) for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-naïve Japanese pre-pubertal children with GHD. The findings were consistent with the results previously reported in the Phase 3 global study.

OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health (OPK) Up 16.4% Since Last Earnings Report: Can It Continue?

OPKO Health, Inc. (OPK) Management Presents at Jefferies Virtual Healthcare Conference (Transcript)

OPKO Health: Current Valuation Creates An Interesting Opportunity

OPKO Health (OPK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OPKO Health (OPK) Upgraded to Strong Buy: Here's Why

MIAMI, June  01, 2020  (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has authorized OPKO to undertake a Phase 2 trial with RAYALDEE® as a treatment for patients with mild-to-moderate COVID-19.  The trial, entitled “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of  R AYALDEE (calcifediol)  E xtended-relea s e  C aps u l e s to Treat Symptomatic Patients Infected with SARS-CoV-2 ( REsCue ),” is estimated to enroll 166 subjects, including many with stage 3 or 4 chronic kidney disease (CKD).

FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients

OPKO Health (OPK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How OPKO Health (OPK) Stock Stands Out in a Strong Industry

OPKO Health (OPK) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors

Why OPKO Health (OPK) Could Be Positioned for a Surge

OPKO Health, Inc. (OPK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: OPKO Health

OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.

OPKO's BioReference Laboratories' Deal Brings Antibody Testing

Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in OPKO Health (OPK) Stock?

The company is rolling out a new COVID-19 testing program for businesses.

Why OPKO Health Shares Were Up 10% Today

As of late, it has definitely been a great time to be an investor in OPKO Health, Inc. (OPK).

OPKO Health, Inc. (OPK) Shares March Higher, Can It Continue?

Its BioReference subsidiary is rolling out testing with five locations -- one in each of NYC's boroughs -- but will quickly expand its footprint.

OPKO Health Unit Providing Coronavirus Antibody Screening in New York City

OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.

News for OPKO Health Stock (OPK)